<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038571</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-596</org_study_id>
    <nct_id>NCT00038571</nct_id>
  </id_info>
  <brief_title>Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy</brief_title>
  <official_title>Phase II Study of Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of Phase II study for B-cell lymphoma using PS341: Evaluate efficacy and toxicity of
      bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm
      B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was
      administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a
      maximum of six cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Response to PS-341</measure>
    <time_frame>Every two 21-day cycles</time_frame>
    <description>Patient response evaluated according to criteria of Cheson et al. Endoscopy obtained every two cycles to evaluate response using Complete Response (CR), Partial Response (PR), Progressive Disease, or Stable Disease.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>Arm A (mantle-cell lymphoma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (other B-cell lymphomas)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PS341 (Bortezomib)</intervention_name>
    <description>1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.</description>
    <arm_group_label>Arm A (mantle-cell lymphoma)</arm_group_label>
    <arm_group_label>Arm B (other B-cell lymphomas)</arm_group_label>
    <other_name>Velcade</other_name>
    <other_name>LPD-341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION:

          -  Relapsed or Refractory B cell lymphoma.

          -  Zubrod status &lt;/= 3.

          -  Measurable disease.

          -  No anti-cancer treatment within past 3 weeks.

          -  ANC &gt;= 1500/uL, Plt &gt;/= 50,000, Bilirubin &lt;2 mg/dL, SGPT &lt;2.5xULN, creatinine &lt;2.
             Patients with ANC&gt;/1000, PLT&gt;/30000 will be eligible if due to massive splenomegaly
             and/or BM involvement.

          -  HIV negative.

          -  No active CNS lymphoma.

          -  No serious intercurrent illness, active infections or cancer except basal cell
             carcinoma of the skin or in situ cervical carcinoma.

          -  Not eligible for treatment of a higher priority. Patients may be entered before BMT.

          -  No pregnancy &amp; age bearing females must be practicing adequate contraception.

          -  Age &gt; 16.

        EXCLUSION:

          -  Patients with platelets &lt;30x10(9)/L within 14 days before enrollment.

          -  Patients with ANC&lt;1.0 x10(9)/L within 14 days before enrollment.

          -  Patients with peripheral neuropathy &gt;/= grade 3 within 14 days before enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Fayad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <results_reference>
    <citation>Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 1;23(4):667-75. Epub 2004 Dec 21.</citation>
    <PMID>15613697</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2002</study_first_submitted>
  <study_first_submitted_qc>May 31, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2002</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>B cell lymphoma</keyword>
  <keyword>Proteasome Inhibitor</keyword>
  <keyword>PS-341</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

